KESTRA MEDICAL TECHNOLOGIES, LTD.
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 30, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jul 31, 2026 | Sep 14, 2026 | After market close | $31.00M | – | – |
| Q4 FY2026 Ended Apr 30, 2026 | Jul 14, 2026 | After market close | $28.60M | – | – |
| Q3 FY2026 Ended Jan 31, 2026 | Mar 17, 2026 | After market close | $24.60M | $-0.61 | – |
| Q2 FY2026 Ended Oct 31, 2025 | Dec 1, 2025 | Before market open | – | – | – |
| Q1 FY2026 Ended Jul 31, 2025 | Sep 11, 2025 | After market close | $19.40M | – | – |
| Q4 FY2025 Ended Apr 30, 2025 | Jul 15, 2025 | After market close | $17.20M | – | – |
| Q3 FY2025 Ended Jan 31, 2025 | Apr 14, 2025 | After market close | $15.10M | $-1.25 | – |
Company guidance
Outlook given with results on Sep 14, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue guidance | FY27 | $141.00M | Raised |
| growth | FY27 | 48% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Kestra Medical Technologies filed with the SEC
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
Material agreement · Agreement terminated · Results of operations · New financial obligation · EX-99.1 to Form 8-K
Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device
Regulation FD disclosure · EX-99.1 to Form 8-K
Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kestra Medical Technologies Reports Third Quarter Fiscal 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K